Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: Combination of cell-penetrating peptides with nanomaterials for the potential therapeutics of central nervous system disorders: a review

Fig. 3

Schematic representation of the in vivo screening platform for the identifification of BBB-penetrating peptides. A novel peptide named M1 (TFYGGRPKRNNFLRGIR) was identifified and further validated (A). In vivo and ex vivo imaging for the validation of the BBB-penetrating ability of the peptides. A peptide with a random sequence was utilized as a negative control, and an RGD motif was appended to the C-terminus of M1 to potentially enhance its tumor targeting ability (B). Schematic representation of the synthesis of peptide − PTX conjugates: M1-PTX and M1-RGD-PTX. Two PTX molecules were attached to one peptide molecule (C). Treatment of triple negative BCBM with PDCs. Tumor suppression monitored by luciferase activity-based bioluminescence imaging (D). Reprinted with permission from ref. [103]. Copyright (2019) American Chemical Society

Back to article page